PROINFLAMMATORY CYTOKINE ENDOTHELIAL MONOCYTE ACTIVATING PEPTIDE II: SERUM LEVEL IN DIABETES
DOI:
https://doi.org/10.11603/1811-2471.2015.v24.i4.5805Abstract
SUMMARY. There was investigated a serum level of endothelial monocyte activating peptide II in type 1 and 2 diabetes and possible relation with carbohydrate metabolism.
It was found an increased serum level of EMAP-II in type 1 and 2 diabetes. There was signifcant correlation between EMAP-II and HbAc1, blood glucose. The revealed change of EMAP-II serum level refects an endothelial dysfunction in type 1 and 2 diabetes, alteration of carbohydrate metabolism could infuence of this pathway.
KEY WORDS: endothelial monocyte activating peptide II, diabetes, endothelial dysfunction.
References
Characterization of a novel tumor-derived cytokine. Endothelial monocyte activating polypeptide II / J. Kao, K. Houck, Y. Fan [et al.] // J. Biol. Chem. – 1994. – Vol. 269. – R. 25106–25119.
Involvement of endothelial-monocyte activating polypeptide II in tumour necrosis factor-alpha-based anti-cancer therapy / T. E. Lans, R. van Horssen, A. M. Egger mont, T. L. ten Hagen // Anticancer. Res. – 2004. – Vol. 24. – R. 2243–2248.
Potential role for antiangiogenic proteins in the myocardial infarction repair process / J. L. Thomp son, J. A. Ryan, M. L. Barr [et al.] // J Surg. Res. – 2004. – Vol. 116 (1). – R. 156–164.
Tooke J. E. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes / J. E. Tooke // J. Diabetes Complications. – 2000. – Vol. 14. – R. 97–200.
Van Horssen R. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes / R. van Horssen, A. M. Eggermont, T. L. ten Ha gen // Cytokine Growth Factor Rev. – 2006. – Vol. 17 (5). – R. 339–348.
Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis / C. Yuan, L. Yan, P. Solanki [et al.] // J. Mol. Cell. Cardiol. – 2015. – Vol. 79. – R. 224–231.
